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ABSTRACT
Background: Stepped-wedge cluster randomised trials
(SW-CRT) are increasingly being used in health policy
and services research, but unless they are conducted
and reported to the highest methodological standards,
they are unlikely to be useful to decision-makers.
Sample size calculations for these designs require
allowance for clustering, time effects and repeated
measures.
Methods: We carried out a methodological review of
SW-CRTs up to October 2014. We assessed adherence
to reporting each of the 9 sample size calculation items
recommended in the 2012 extension of the CONSORT
statement to cluster trials.
Results: We identified 32 completed trials and 28
independent protocols published between 1987 and
2014. Of these, 45 (75%) reported a sample size
calculation, with a median of 5.0 (IQR 2.5–6.0) of the
9 CONSORT items reported. Of those that reported a
sample size calculation, the majority, 33 (73%),
allowed for clustering, but just 15 (33%) allowed for
time effects. There was a small increase in the
proportions reporting a sample size calculation (from
64% before to 84% after publication of the CONSORT
extension, p=0.07). The type of design (cohort or
cross-sectional) was not reported clearly in the
majority of studies, but cohort designs seemed to be
most prevalent. Sample size calculations in cohort
designs were particularly poor with only 3 out of 24
(13%) of these studies allowing for repeated measures.
Discussion: The quality of reporting of sample size
items in stepped-wedge trials is suboptimal. There is
an urgent need for dissemination of the appropriate
guidelines for reporting and methodological
development to match the proliferation of the use of
this design in practice. Time effects and repeated
measures should be considered in all SW-CRT power
calculations, and there should be clarity in reporting
trials as cohort or cross-sectional designs.
BACKGROUND
The parallel cluster randomised trial (CRT)
is commonly used in the evaluation of inter-
ventions delivered at the level of the
cluster.1–3 In the conventional parallel CRT
at the beginning of the trial, half of the clus-
ters are randomised to the intervention and
half to the control. In the stepped-wedge
CRT (SW-CRT), clusters are sequentially ran-
domised to cross from the control to inter-
vention arm.4–6 Systematic reviews examining
the types of interventions and breadth of use
of this trial design show that while its use is
still relatively rare compared with other study
designs it is on the increase.4 5 Furthermore,
a recent review, focusing on the scope of
interventions and rationale for the use of the
design, suggests there has been a dramatic
increase in the number of published
SW-CRTs within the last couple of years.7
In parallel CRTs it is well known that
sample size calculations and analysis should
take into account the clustered nature of the
data.8 9 Sample size calculations which do
not make allowance for this clustering under-
estimate the sample size needed, and analysis
without adjusting for clustering leads to
overly precise estimates of treatment effects.
Allowance for clustering at the design stage
of a parallel CRT simply requires inﬂation of
the sample size needed under individual
Strengths and limitations of this study
▪ This is the first systematic review of stepped-
wedge cluster randomised trials (SW-CRTs) to
assess reporting adherence to CONSORT items.
▪ This high-quality systematic review has well-
defined inclusion criteria, used double data
abstraction throughout and clearly defines how
items were classified and abstracted.
▪ This review identifies not only whether SW-CRTs
are reporting sample size calculations, but also
identifies whether the appropriate power calcula-
tion was used.
▪ While reporting of adherence to guidelines
demonstrates quality of reporting, our review did
not replicate sample size calculations.
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randomisation by the design effect for parallel cluster
trials.7 8 There are variations on this design effect for
unequal cluster sizes.10 11
When using a SW-CRT, the evaluation happens over a
period of time, and during this period of time, the pro-
portion of clusters which are exposed to the interven-
tion gradually increases. See ﬁgure 1 for an illustration
of the SW-CRT. This means that the control clusters, will
on average, contribute observations from an earlier cal-
endar time than the intervention clusters. Calendar time
is therefore a potential confounder and will have to be
adjusted for in the analysis. Furthermore, in SW-CRTs, at
each measurement occasion, the sample may be consist-
ent of different individuals (ie, cross-sectional), or it
might consist of the same individuals measured repeat-
edly over time (ie, cohort design). Because of this,
sample size calculations for SW-CRTs should make allow-
ance for both the clustered nature of the data and calen-
dar time, and make an allowance for any repeated
measures on the same individuals.
Hussey and Hughes12 ﬁrst derived a method of esti-
mating the power available from a SW-CRT which makes
allowance for both the clustering and the time effects.
Subsequent to this, a design effect for stepped-wedge
studies has been derived, which allows determination of
number of clusters needed for a given cluster size and
number of steps.13–15 As yet, there is no adjustment to
these design effects available to account for designs
which involve repeated measurements on the same indi-
viduals. We do not present the design effect for the
SW-CRT here as it is algebraically complicated but it can
be found in the referenced papers.
Transparent reporting of clinical trials allows critical
appraisal and assessment of the robustness of results.16
The CONSORT (consolidated standards for reporting)
statement for individually randomised controlled trials
(RCTs) recommends that sufﬁcient information be pro-
vided to allow replication of the sample size calcula-
tion.17 18 For parallel CRTs, there are additional
recommendations.19 20 Furthermore, reporting of the
method used to determine the sample size allows assess-
ment of methodological rigour. There is as yet no
CONSORT extension for SW-CRTs, although one is in
development21 and several extension items have been
recommended for reporting.6 However, as SW-CRTs are
a form of cluster RCTs, they should—as a minimum—be
reported according to the CONSORT extension
for CRTs.
Early CRTs were often underpowered and analysed
incorrectly.21 Although sample size methodology and
reporting guidelines for parallel CRT designs are now
well established, the quality of their reporting is still
assessed as being inadequate.22–24 But, little evidence is
available on the quality of reporting, or methodological
rigour, in SW-CRTs. This is because the systematic
reviews of SW-CRTs to date have been small; or have not
assessed adherence to reporting of the sample size calcu-
lation in accordance with CONSORT guidance; and
have also not assessed whether the sample size method-
ology matches the design of the study.4 5 7 While it is
well known that sample size reporting, particularly from
studies using complex designs is poor, highlighting areas
of poor performance in the SW-CRT design early on will
potentially mitigate any poor practices becoming routine
poor practices. It will also allow identiﬁcation of items of
importance to be considered for inclusion in the
CONSORT extension. We have therefore undertaken a
methodological review of SW-CRTs, evaluating adher-
ence to the CONSORT cluster extension and assessment
of methodological rigour of the sample size method-
ology used. This review forms a preparatory step in the
development of the CONSORT extension for the
SW-CRT, and will form one of a number of distinct
bodies of work needed in the build up to this
extension.20
Our speciﬁc objectives were to carry out a systematic
review of published SW-CRTs to (1) determine adher-
ence to reporting each of the sample size items recom-
mended in the 2012 extension to the CONSORT
statement to cluster trials; (2) identify the power meth-
odology used in these designs; and (3) determine
whether the appropriate methodology is being used,
with particular emphasis on whether these trials are
making allowance for both the clustered nature of the
data; the time effects associated with the stepped-wedge
design; and any repeated measures on the same
individuals.
METHODS
Search strategy
We used an adaptation of two previously published
search strategies.4 5 This search strategy is described in
full in online supplementary ﬁgure S1, and included all
protocols (not yet published as full trial reports) and
independent full trial reports of SW-CRTs in both
healthcare and non-healthcare settings. To meet our
deﬁnition of a SW-CRT, the study had to be a rando-
mised trial, use cluster randomisation, and have two or
more steps. We excluded trials which were not published
in English, individually randomised trials, trials with
cross-over designs, non-randomised designs or trials
which were retrospectively analysed as stepped-wedge
studies. We only included original research studies and
primary study reports.
We searched MEDLINE, EMBASE (including Embase
classic) and PsycINFO, up to 23 October 2014. The titles
and abstracts of the studies identiﬁed were screened
independently by two authors (JM and one other
author). Full-text articles were obtained for all poten-
tially eligible studies and the same duplicate method of
assessment used. Those found not to meet the eligibility
criteria were excluded at this stage and tabulated by
reason for exclusion. Any differences of opinion were
resolved by discussion with all authors. We also screened
reference lists of studies found to meet the inclusion
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criteria. We did not contact authors of papers for add-
itional information as our primary intention was to
assess quality of reporting.
We did not access published or unpublished trial pro-
tocols even if they were cited in the fully published trial
report. Our motivation here was that in an assessment of
reporting quality, reporting of important items (such as
the sample size) should be complete in the full report
and it should not be necessary to abstract information
from elsewhere. To increase the available number of
studies for our review, we abstracted a selection of items
from study protocols which had yet to be published as
completed trial reports.
Data abstracted from trial reports
Data for all studies meeting the eligibly criteria were
abstracted by two independent reviewers in random
order. Any differences were resolved by consensus dis-
cussion with all authors. A data abstraction form was
developed and tested on a small number of studies and
then reﬁned. Abstracted items are summarised in online
supplementary table S1.
Data abstracted on basic trial characteristics
We report the trial characteristics (for completed trials
as well as subgroup of protocols only), including year of
publication, country (broadly categorised into higher,
lower or middle income country),25 journal impact
factor (taken from Web of Science, JCR Science Edition
2013), type of cluster, health setting or non-health
setting, number of interventions compared, whether any
restriction was used in the randomisation procedure and
the type of primary outcome (binary, continuous, count,
etc).
For completed trials, we also summarised the design
features speciﬁc to the SW-CRT, including the duration
of the study, number of steps (deﬁned as the number of
randomisation points), total number of clusters, number
of clusters randomised at each randomisation step,
whether the design was cohort or cross-sectional, cluster
size (for cohort studies this is total number of observa-
tions made across the cluster), and whether any varia-
tions on the conventional stepped-wedge design was
used (eg, extended pre-period and postperiod). We also
collected information on the median duration between
two successive randomisation points, and the number of
distinct data measurement points, which in a conven-
tional SW-SCT is simply one greater than the number of
steps. If there was a difference between planned and rea-
lised design features, we used the realised design
features.
Data abstracted on sample size reporting
For completed trials, as well as for the subgroup of trials
with a protocol only, we then reported adherence to
recommendations for sample size calculations as speci-
ﬁed in the CONSORT 2010 statement,17 the cluster
extension18 19 and those recommended for stepped-
wedge studies.6 Items relating to the quality of reporting
of the basic sample size included reporting of: (1) the
signiﬁcance level, (2) the power and (3) the treatment
effect; (4) whether there was consistency between
primary outcome and power outcome; (5) whether or
not attrition was accounted for; (6) the anticipated
cluster size (or number of clusters); (7) the assumed
intracluster correlation (ICC) or equivalent; (8) a
measure of variation or uncertainty of the ICC; and (9)
a measure of variation in cluster sizes. We deemed the
treatment effect to be sufﬁciently reported if there was:
a standardised effect size; a mean difference and SD;
means in both arms and SD; proportions in both arms;
proportion in one arm and an absolute or relative
difference.
Elements relating to the quality of reporting of the
stepped-wedge sample size included reporting of the
number of steps; number of clusters randomised per
Figure 1 Schematic illustration of the stepped-wedge cluster randomised trial.
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step; whether a schematic representation was provided;
whether there was explicit clarity over whether the
design was cohort or cross-sectional; and whether there
was clarity over total cluster size and cluster size per
measurement point.
All items that were not clearly reported were classiﬁed
as either unclear or deducible if they could be derived
unambiguously from other reported items.
Data abstracted on methodological rigour of sample size
calculation
To assess methodological rigour of the power and
sample size calculations, we abstracted information on
how these calculations were undertaken. This informa-
tion was abstracted for completed trials, as well as for
the subgroup of trials with a protocol only. Of primary
interest was whether the calculation adjusted for cluster-
ing, time effects and any repeated measures on the
same individual. For those studies adjusting the power
calculation for time effects, we determined whether the
authors made reference to using the Hussey and
Hughes methodology,11 the Woertman design effect12 or
an alternative method which we noted. For cohort
designs, we abstracted information on whether allowance
was made for repeated measures on the same individual.
Information was also abstracted on whether this power
calculation included allowance for any transition
periods;26 plans to explore whether the effect varies with
time since exposure (ie, a learning or lag effect); or any
extended correlation structures, such as an allowance
for the within cluster correlation to differ for observa-
tions within different measurement periods.27 We also
abstracted information on whether there was any allow-
ance for varying cluster size.
Analysis of results
We ﬁrst summarise the basic trial demographics of the
full trial reports and the trial protocols. We stratify this
analysis by type of report (full trial report and protocol),
as we expected trial protocols may be of a different
demographic to the full trial report. We observed little
difference between the study characteristics of the full
reports and trial protocols, and so all other analyses
were pooled across full trial and protocols. We then sum-
marise the realised design characteristics of the included
full trial reports.
To explore whether the publication of the CONSORT
extension for cluster trials might have improved quality
of reporting, we stratiﬁed by trials published before and
during 2012 (the date of the publication of the cluster
CONSORT extension19) and those published during or
after 2013. While the CONSORTextension does not spe-
ciﬁcally address stepped-wedge cluster trials, stratiﬁcation
still allows investigation of any improvement over time.
Improvements were described using absolute differences
with 95% CIs. We tested these differences using a χ2 test
for proportions, Fisher’s exact test for low counts or a
Mann-Whitney U test for continuous data.
RESULTS
The searches identiﬁed 3248 studies of which 1218 were
immediately identiﬁed as duplicates and 1696 were
excluded on the initial abstract screen, leaving 334 full-
text articles which were assessed for eligibility. Of these,
we excluded 274 (details in ﬁgure 2) after a careful
screen of the full paper. From this, we were left with 32
full trial reports and 28 trial protocols for inclusion in
the review. A list of the included studies is provided in
online supplementary appendix 1.
The trial characteristics of the 28 trial protocols and
32 full reports are summarised in table 1. Over half of
both protocols and full reports were published during
or after 2013. A large proportion of trials were con-
ducted in higher income countries, and the majority
(83.3%) were conducted in health settings. Examples of
studies in non-healthcare settings included a study evalu-
ating the effect of free school meals on academic
Figure 2 Flow chart showing studies identified by the
systematic review. SW, stepped-wedge.
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attainment and an intervention to mitigate absenteeism
in the workplace. Almost all studies compared two inter-
ventions (ie, standard care/control and a new interven-
tion). The majority of studies used a simple, unrestricted
form of random allocation, but a few studies used paired
or stratiﬁed allocation methods. Almost 60% of the
studies had a binary primary outcome, with continuous
outcomes being less common.
Among the 32 completed studies (table 2), the median
number of randomisation steps was 4 (IQR 2–6); the
median number of clusters 17 (IQR 8–38); and the
median cluster size (across all measurement points) was
55 (IQR 24–326). Only 5 (15.6%) of the 32 completed
studies were of cross-sectional design, with the majority
being cohort (37.5%) or open cohort (31.3%) designs.
Overall, 17 variations on the typical stepped-wedge
design were observed, the most common of which was
extended pre-period or postperiod (10 studies).
Overall, 45 (75.0%) of the trials reported a sample
size justiﬁcation (table 3). The median number of
CONSORT items reported across all 60 studies was 5
(IQR 2–6). None of the studies reported all nine
CONSORT items. Almost all of the studies reported the
number of clusters (96.7%). Approximately, 55% of the
studies reported an ICC or equivalent, but few studies
reported any variation in cluster size or reported any
uncertainty in the estimation of the ICC. Allowance for
attrition was poorly reported with only 30.0% of studies
clearly reporting this item. We observed some improve-
ment in reporting over time, most notably, reporting of
the ICC increased from 39.3% pre-2012 to 68.8%
post-2013 (p=0.022).
Almost all trials reported the number of steps (90%),
or this was deducible (98.3%), and 93.3% reported the
number of clusters randomised per step (table 4). Many
studies reported a schematic representation of the
Table 1 Basic trial demographics of included SW-CRTs, values are numbers (percentages) unless stated otherwise
Total
N=60
Protocols
N=28
Full reports
N=32
Year of publication
1987–2012 28 (46.7) 12 (42.9) 16 (50.0)
2013–2014 32 (53.3) 16 (57.1) 16 (50.0)
Journal Impact Factor
Median (IQR) 2.6 (2.0–3.5) 2.3 (2.1–4.8) 3.3 (2.0–4.8)
Country of study
Australia 7 (11.7) 6 (21.4) 1 (3.1)
Canada or USA 15 (25.0) 4 (14.3) 11 (34.4)
UK or Ireland 11 (18.3) 3 (10.7) 8 (25.0)
Other higher income country 15 (25.0) 9 (32.1) 6 (18.8)
Middle-income country 9 (15.0) 4 (14.3) 5 (15.6)
Low-income country 3 (5.0) 2 (7.1) 1 (3.1)
Type of setting
Healthcare 50 (83.3) 25 (89.3) 25 (78.1)
Non-healthcare 10 (16.7) 3 (10.7) 7 (21.9)
Cluster
General practice 7 (11.7) 6 (21.4) 1 (3.1)
Hospital/ward/specialties 12 (20.0) 5 (17.9) 7 (21.9)
Other health cluster 20 (33.3) 9 (32.1) 11 (34.4)
Geographical unit 11 (18.3) 5 (17.9) 6 (18.8)
Other/unclear 10 (16.7) 3 (10.7) 7 (21.9)
Number of study arms
Two 56 (93.3) 25 (89.3) 31 (96.9)
Three or more 4 (6.7) 3 (10.7) 1 (3.1)
Randomisation type
Simple 35 (58.3) 15 (53.6) 20 (62.5)
Paired 4 (6.7) 0 (0) 4 (12.5)
Stratified 14 (23.3) 10 (35.7) 4 (12.5)
Other/unclear 7 (11.7) 3 (10.7) 4 (12.5)
Primary outcome type
Continuous 15 (25.0) 10 (35.7) 5 (15.6)
Binary 34 (55.7) 13 (4.4) 21 (65.6)
Other 5 (8.3) 2 (7.1) 3 (9.4)
Unclear/not reported 6 (10.0) 3 (10.7) 3 (9.4)
Published protocol NA 5 (15.6)
NA, not available; SW-CRT, stepped-wedge cluster randomised trial.
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design (76.7%). However, only 26.7% of the trials expli-
citly reported whether the trial design was cross-sectional
or cohort in nature; this increased to 71.7% when we
made use of other reported items to deduce the type of
design. In about 50% of the studies, it was unclear
whether the cluster size reported in the sample size cal-
culation related to the cluster size per measurement
period or the total cluster size.
Our methodological assessment revealed that the
majority (73.3%) allowed for clustering within the
sample size calculation, but that only 33.3% allowed for
time effects within the sample size calculation (table 5).
Approximately 30% of the studies used the Hussey and
Hughes methodology, with a small number using differ-
ent methods which still allow for time effects. Fourteen
(31.1%) of the studies reported using a methodology
which clearly did not allow for time effects and a
substantial number of studies (33.3%) did not report
which methodology they used. Few studies incorporated
additional design features into their power calculation
(such as extended pre and post periods). There was an
increase over time in the percentage of studies allowing
for time effects from 16.7% pre-2012 to 44.4% post-2013
(p 0.063).
DISCUSSION
We have carried out a methodological review to assess
the quality of reporting and methodological rigour of
sample size calculations in SW-CRTs. Of particular note,
less than half of the trials in our review allowed for the
temporal nature of the design in the power or sample
size calculation. We also found that few studies acknowl-
edged any repeated measures on the same individuals—
yet, the majority of studies used a cohort design. Related
to this, few studies explicitly described whether the study
was cross-sectional or cohort in design, and in many
studies, there was lack of clarity over whether the cluster
size used in the sample size calculation was the total
cluster size or the cluster size per measurement period.
It is known that lack of allowance for time effects in
the sample size calculation for a SW-CRT can result in
either an underpowered or overpowered trial.13 Early
users of the parallel cluster trial failed to realise that
sample size calculations required allowances for cluster-
ing, and this resulted in decades of underpower trials.21
Identiﬁcation of similar oversights in the design of
SW-CRTs at a time when they are just beginning to
experience an upsurge in popularity might prevent
similar years of poor practice. Furthermore, improve-
ment with respect to clarity of reporting trials as cohort
or cross-sectional would be a simple but important ﬁrst
step. Identiﬁcation of these areas of poor performance
can be used in the initial phase of the Delphi consensus
study as potential items for inclusion in the CONSORT
extension.21
We found that studies almost always reported the
number of steps and the number of clusters randomised
at each step, and a large majority provided a schematic
representation of the trial design. Furthermore, many
allowed for clustering. We observed some indication that
the quality of reporting and methodological rigour
improved in studies published after the publication on
the most recent CONSORT extension for cluster trials.
Many of the recent studies published were protocols,
and so some of this improvement in quality might be
attributable to the type of report (protocol or full
report).28 However, in our analysis (not shown), we
found little evidence of a difference between protocols
and full reports.
The majority of studies used the Hussey and Hughes
method to compute the power. The methodology
proposed by Hussey and Hughes has some limitations.
First, it does not immediately allow repeated measures
on the same individual—yet, over half of the studies
Table 2 Summary of the realised design features of the
included stepped-wedge cluster randomised trial. Values
are numbers (percentages) unless stated otherwise
Full trial report
N=32
Number of steps*
Two 9 (28.1)
Three or four 8 (25.0)
More than four 14 (43.8)
Not reported 1 (3.1)
Median (IQR) 4.0 (2.0–6.0)
Number of clusters
Less than 10 9 (28.1)
10 or more 22 (68.8)
Not reported 1 (3.1)
Median (IQR) 17.0 (8.0–38.0)
Total cluster size†
Median (IQR) 55.0 (24.0–326.0)
Number of clusters randomised per step
Median (IQR) 3.0 (1.0–8.0)
Number of measurement points‡
Median (IQR) 5.0 (3.0–7.5)
Study duration (months), median (IQR) 16.0 (8.0–24.0)
Step duration (months), median (IQR) 2.0 (1.0–4.0)
Design type§
Cross-sectional 5 (15.6)
Cohort 12 (37.5)
Open cohort 10 (31.3)
Unclear 5 (15.6)
Variations on design
Transition periods 1 (3.1)
Extended pre-period or postperiod 11 (34.4)
Other 6 (18.8)
*Steps are points at which clusters are randomised.
†For cohort studies this is the total number of observations made
within the cluster, it includes the size of clusters in which there
was lack of clarity of cluster size and cluster size per
measurement period but for which a judgement was made.
‡Measurement points are the number of separate periods or
points in time in which outcome data are collected.
§Design type includes those for which there was lack of clarity but
for which a judgement was made.
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Table 3 Quality of reporting of basic sample size elements from the CONSORT 2010 statement and the Cluster 2012
extension to the CONSORT statement
All studies
N=60
1987–2012
N=28
2013–2014
N=32
Absolute difference
(95% CI) p Value
Sample size justification
Reported 45 (75.0) 18 (64.3) 27 (84.4) 20.1 (−1.7 to 41.8) 0.073
Item 1
Level of significance 39 (65.0) 16 (57.1) 23 (71.8) 14.7 (−9.3 to 38.8) 0.233
Item 2
Power 45 (75.0) 18 (64.3) 27 (84.4) 20.1 (−1.7 to 41.8) 0.073
Item 3
Treatment effect† 33 (55.0) 15 (53.6) 18 (56.3) 2.7 (−22.6 to 27.9) 0.835
Item 4
Consistency with primary outcome 38 (63.3) 14 (50.0) 24 (75.0) 25.0 (1.2 to 48.8) 0.045
Item 5
Allowance for attrition 18 (30.0) 7 (25.0) 11 (34.4) 9.4 (−13.6 to 32.4) 0.429
Item 6
Number of clusters 58 (96.7) 27 (96.4) 31 (96.9) 0.4 (−8.7 to 9.6) 0.923
Median cluster size 39 (65.0) 15 (53.6) 24 (75.0) 21.4 (−2.4 to 45.2) 0.083
Item 7
Variation in cluster size* 6 (10.0) 1 (3.6) 5 (15.6) 12.1 (−2.3 to 26.4) 0.201
Item 8
Variation in outcome across
clusters (ie, ICC)
33 (55.0) 11 (39.3) 22 (68.8) 29.5 (5.3 to 53.7) 0.022
Item 9
Uncertainty of ICC (or equivalent)* 8 (13.3) 3 (10.7) 5 (15.6) 4.9 (−12.1 to 21.9) 0.712
All ItemS
Number items reported median (IQR) 5.0 (2.5–6.0) 4.0 (1.0–6.0) 6.0 (5.0–6.0) 1.22 (0.07 to 2.36) 0.067
Reporting all nine items 0 (0) 0 (0) 0 (0)
Values are numbers (percentages) unless stated.
p Value is for the comparison of 1987–2012 publications and 2013–2014 publications using a χ2 test for proportions (categorical outcomes) or
Mann-Whitney U test (where medians are reported), or (*) using Fisher’s exact test.
†A sufficient reporting of the treatment effect consists of either a standardised effect size; a mean difference and SD; means in both arms and
SD; proportions in both arms; proportion in one arm and a difference.
ICC, intracluster correlation.
Table 4 Reporting of stepped-wedge cluster randomised trial sample size elements according to the proposed modification
to the Cluster 2012 extension for cluster randomised trials
All reports
N=60
1987–2012
N=28
2013–2014
N=32
Absolute difference
(95% CI) p Value
Number of steps
Explicitly reported 54 (90.0) 23 (82.1) 31 (96.9) 14.7 (−0.7 to 30.1) 0.058
Reported or deducible 59 (98.3) 27 (96.4) 32 (100.0) 3.6 (−3.3 to 10.4) 0.281
Number clusters randomised per step
Reported 56 (93.3) 25 (89.3) 31 (96.9) 7.6 (−5.4 to 20.5) 0.240
Schematic representation
Reported 46 (76.7) 20 (71.4) 26 (81.3) 9.8 (−11.7 to 31.3) 0.370
Design type (ie, cross-sectional/cohort)
Explicitly reported 16 (26.7) 6 (21.4) 10 (31.3) 9.8 (−12.3 to 31.9) 0.391
Reported or deducible 43 (71.7) 19 (67.9) 24 (75.0) 7.1 (−15.8 to 30.0) 0.540
Clarity of cluster size†
Total cluster size reported 17 (28.3) 8 (28.6) 9 (28.1) −0.4 (−23.3 to 22.4) 0.969
Cluster size per measurement period reported 25 (41.7) 10 (35.7) 15 (46.9) 11.2 (−13.6 to 35.9) 0.382
Unclear/not reported 29 (48.3) 15 (53.6) 14 (43.8) −9.8 (−35.1 to 15.4) 0.448
Values are numbers (percentages) unless stated otherwise.
p Value is for the comparison of 1987–2012 publications and 2013–2014 publications using a χ2 test for proportions.
†Some studies reported both total cluster size and cluster size per measurement period.
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involved repeated measures using a cohort or open
cohort design. Second, it assumes normality; whereas no
previous studies have examined its application in the
case of deviation from normality, more than half of the
studies had a categorical primary outcome. Further
methodological work is required to address these issues.
Recent methodological developments do now mean it
is possible to determine the cluster size given other
ﬁxed design constraints, determine the number of clus-
ters or number of steps needed13 Furthermore, a user-
friendly sample size calculator to carry out these calcula-
tions has been developed and is available as an add-on
function in the Stata statistical package.29 While some
SW-CRTs might be very pragmatic and sample size deter-
mined by the number of observations available, properly
designed evaluations should include a robust justiﬁca-
tion for the sample size. In implementation research
and the evaluation of service delivery interventions, this
will be necessary to justify funding resources needed to
undertake the evaluation.
Implications
Whereas sample size calculations that do not allow for
the effect of clustering are likely to lead to underpowered
SW-CRTs, those that do not allow for the effect of time
might lead to studies being either underpowered or over-
powered.13 For the case where the ICC is low, designing a
SW-CRTusing methodology for a parallel study is likely to
lead to an underpowered study. Absolute differences in
magnitude of power might be fairly low, for example, in
the region of 10%. However, when the ICC is higher,
designing a SW-CRT using methodology for a parallel
design is bound to lead to an overpowered design at the
expense of including vast numbers of observations which
may contribute little to the power.13 Less work has been
carried out on the drawbacks of powering a cohort
SW-CRT as if it were of a cross-sectional design. However,
repeated measures taken on the same individuals are
likely to induce a reduction in variance of the treatment
effect, and so lead again to a larger sample size than
needed. Larger sample sizes than needed have important
ethical implications. Bias in estimates of treatment effects
is viewed by many to be more important than any lack of
precision, and biases will not be prevalent unless the
study did not take into account the time effects at the
analysis stage. Whether or not allowances for time effects
at the analysis stage are more frequent than at the design
stage is not something we have considered, though it
would seem unlikely that these mistakes are rectiﬁed if
they are missed at the design stage.
Researchers need to specify estimates of ICCs in
advance—as with any other cluster trial. While allowance
for time effects are needed in the power calculation,
these do not require any judgements or estimations, but
Table 5 Methodological assessment sample size calculations and trial justification in SW-CRTs, among those studies
reporting a sample size calculation
All reports
N=45
1987–2012
N=18
2013–2014
N=27
Absolute difference
(95% CI) p Value
Allowance for clustering
Number (%) 33 (73.3) 11 (61.1) 22 (81.5) 20.4 (−6.5 to 47.2) 0.130
Allowance for time effects
Number (%)* 15 (33.3) 3 (16.7) 12 (44.4) 27.8 (2.3 to 53.2) 0.063
Allowance for repeated measurements†*
Number (%) 3/24 (12.5) 2/11 (18.2) 1/13 (7.7) −10.5 (−37.5 to 16.5) 0.576
Power methodology
Hussey and Hughes 14 (31.1) 3 (16.7) 11 (40.7) 24.1 (−1.2 to 49.4) 0.087
Other, allowing for time effects* 2 (4.4) 0 (0) 2 (7.4) 7.4 (−2.5 to 17.3) 0.509
Other, not allowing for time effects 14 (31.1) 10 (55.6) 4 (14.8) −40.7 (−67.3 to −14.2) 0.004
Not stated 15 (33.3) 5 (27.8) 10 (37.0) 9.3 (−18.3 to 36.8) 0.519
Power methodology for additional features
Transition periods 0 (0) 0 (0) 0 (0)
Interactions (eg, lag effects) 0 (0) 0 (0) 0 (0)
Extended correlations* 2 (4.4) 2 (11.1) 0 (0) −11.1 (−25.6 to 3.4) 0.155
Varying cluster size* 3 (6.7) 1 (5.6) 2 (7.4) 1.9 (−12.6 to 16.3) 1.000
Variation in outcomes across clusters‡
Reported using ICC 20/33 (60.6) 8/11 (72.7) 12/22 (54.6) −18.2 (−51.7 to 15.4) 0.314
Reported using CV* 10/33 (30.3) 2/11 (18.2) 8/22 (36.4) 18.2 (−12.2 to 48.6) 0.430
Reported using DE* 1/33 (3.0) 1/11 (9.1) 0/22 (0) −9.1 (−26.1 to 7.9) 0.333
Reported using between cluster variation* 2/33 (6.1) 0/11 (0) 2/22 (9.1) 9.1 (−2.9 to 21.1) 0.542
Values are numbers (percentages) unless stated otherwise by year of publication.
p Value is for the comparison of 1987–1990 publications and 2013–2014 publications using a χ2 test for proportions or (*) using Fisher’s exact
test.
†Among those with a cohort design.
‡As a percentage of studies for which some measure of variation was reported.
CV, coefficient of variation; DE, design effect; ICC, intracluster correlation; SW-CRT, stepped-wedge cluster randomised trial.
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are simply based on setting the number of steps, the
number of clusters randomised per step and the average
size of the cluster per step. When repeated measures are
taken on the same individuals, then some speciﬁcation
will be needed on the strength of the correlation within
individuals over time.26 However, sample size methods
for SW-CRTs with repeated measures on the same indivi-
duals are yet to be developed.
How our review differs from those already carried out
Other systematic reviews have been conducted to assess
quantity and breadth of SW-CRTs.4 5 7 None of these
reviews systematically assessed quality of reporting
against the existing CONSORT statements and none
assessed methodological rigour of sample size calcula-
tions. Our assessment of quality of reporting of sample
size elements and of the methodological rigour of
sample size calculations highlighted areas of poor per-
formance. Identiﬁcation of these areas of poor perform-
ance early in the use of this design will help mitigate
these poor practices becoming common practices.
In previous reviews assessing quality of reporting in
parallel cluster trials, assessments have been made
against a smaller number of items recommended in the
2004 extension to the CONSORT statement to cluster
trials.23 Here, we have made assessments against the
2012 extension to the CONSORT statement to cluster
trials, even though many trials were designed before this
reporting guideline was published. This is because our
primary motivation was not to assess adherence to guide-
lines, but assess quality of reporting. Publication of
CONSORT statements have been found to be associated
with limited increases in the quality of reporting, and
our ﬁndings are consistent with this.30–32 Interestingly,
the most notable temporal trends we observed were for
CONSORT and CONSORT cluster items and not
stepped-wedge items.
Study limitations
We assessed reporting according to the CONSORT
guidelines for individually randomised trials and the
extension for CRTs. Some of these reporting items do
not extend naturally to the stepped-wedge design. For
example, the CONSORT statement for RCTs recom-
mends that authors report whether attrition has been
taken into account in the sample size calculation.
However, SW-CRTs are often used in the evaluation of
service delivery interventions and implementation
research where outcomes are routinely collected and
attrition is unlikely to be an issue. Similarly, in cross-
sectional designs (15% of our sample), attrition is
unlikely to be an issue. Trials not reporting acknowl-
edgement of attrition might do so simply because it is
not relevant.
We attempted to assess methodological rigour of the
published sample size calculations. We did this by
extracting information on the methodology cited for the
sample size or power calculation; we did not replicate
these calculations. However, we were able to ascertain
how many studies seem to use the appropriate method-
ology. The vast majority of the trials were published
before the design effect for SW-CRTs was established12—
indeed, only one study used this approach.
CONCLUSIONS
As expected, the quality of reporting of sample size cal-
culations in SW-CRTs is suboptimal, and although there
has been some improvement over time, a signiﬁcant
number of studies are not clearly identifying whether
the study used a cross-sectional or cohort design; less
than half allowed for the temporal nature of the design
in the power calculation; and few acknowledged any
repeated measures on the same individuals. This means
that the majority of studies are not using a sample size
methodology that matches the study design. While there
is a need for further methodological development, we
have identiﬁed speciﬁc areas for improvement that are
relatively easy for authors to address. These areas of
poor quality can be used as initial items to go forward
into the consensus agreement needed for the guidelines
of reporting for SW-CRTs.
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